Endometrial cancer trials in Canada

In Canada 34 Also abroad 395

34 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
Montreal, St. John's, Toronto
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Barrie, London, Montreal, Sault Ste. Marie, Sherbrooke, St. John's, Surrey, Toronto, Windsor, Winnipeg
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Halifax, Montreal, Toronto
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Where
Calgary, Montreal, Vancouver
Age
18 years and over
People
660 worldwide
Run by
Genmab
See details and how to joinNCT07166094
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Where
Montreal, Toronto
Age
18 years and over
People
600 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286331 · EU 2025-523362-25-00
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Where
Montreal, Toronto
Age
18 years and over
People
610 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07684599 · EU 2025-523363-37-00
Phase 2Not yet taking people in Canada
Adaptive Radiotherapy for Safe Hypofractionation
Where
Montreal
People
264
Run by
Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT07516210
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Edmonton, Toronto, Vancouver
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 2Taking people
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Where
Barrie, Calgary, Edmonton, Hamilton, Kelowna, London, Mississauga, Montreal, Prince George, Sherbrooke, Toronto, Vancouver, Victoria
Age
18 years and over
People
393 worldwide
Run by
Canadian Cancer Trials Group
See details and how to joinNCT05640999
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Calgary, Montreal, Ottawa, Toronto, Vancouver
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Calgary, Edmonton, Halifax, London, Montreal, Québec, Toronto, Winnipeg
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
No phaseTaking people
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Where
Montreal
Age
18 years and over
People
50
Run by
McGill University Health Centre/Research Institute of the McGill University Health Centre
See details and how to joinNCT07871838
Phase 3Taking people
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Where
Hamilton, Kelowna, Kingston, London, Montreal, Regina, Saint John, Saskatoon, Sherbrooke, Toronto, Vancouver, Victoria
Age
18 years and over
People
316 worldwide
Run by
Leiden University Medical Center
See details and how to joinNCT05255653 · EU 2023-503267-42-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Edmonton, London, Montreal, Toronto
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2Taking people
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
Where
Toronto
Age
18 years to 41 years
People
71
Run by
GynOncTrials
See details and how to joinNCT06073184
Phase 2Not yet taking people in Canada
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
Where
Kingston, Montreal, Ottawa, Toronto, Vancouver
Age
18 years and over
People
30
Run by
University Health Network, Toronto
See details and how to joinNCT07840443
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Montreal, Québec, Toronto
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseTaking people
ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial
Where
Edmonton, Toronto
Age
18 years and over
People
148
Run by
University of Alberta
See details and how to joinNCT06038032
Phase 1/2Taking people
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Where
Hamilton, Montreal, Toronto
Age
18 years and over
People
47 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07213609
No phaseTaking people
Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire
Where
Vancouver
Age
30 years and over
People
30
Run by
University of British Columbia
See details and how to joinNCT07194551
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Toronto
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 3Taking people
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Where
Edmonton, Hamilton, Kingston, Montreal, Winnipeg
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Montreal, Toronto
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 2Taking people
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Where
Montreal, Toronto
Age
18 years and over
People
80 worldwide
Run by
MacroGenics
See details and how to joinNCT06730347
No phaseNot yet taking people in Canada
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
Where
Vancouver
Age
35 years and over
People
50
Run by
University of British Columbia
See details and how to joinNCT07581288